Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis

Oncology Research, Vol.28, No.7-8, pp. 811-814, 2020, DOI:10.3727/096504020X15965357399750

Abstract Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML relapse, seven patients received induction chemotherapy and two More >

Ching-Wen Huang^*, Cheng-Jen Ma^*†, Wei-Chih Su^*, Yi-Ting Chen^‡§, Hsiang-Lin Tsai^*¶, Yung-Sung Yeh^*#, Tsung-Kun Chang^*, Wen-Hung Hsu^**††, Fang-Jung Yu^**††, Jaw-Yuan Wang^{*¶‡‡§§¶¶##}

Oncology Research, Vol.28, No.7-8, pp. 701-714, 2020, DOI:10.3727/096504020X15986099915822

Abstract This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy with oral capecitabine (daily dose of 850 mg/m2 , twice daily, on days 1–14 every 3 weeks for 6 months) on survival according to treatment group and EGFR expression were analyzed. By conducting an in vitro cell line study… More >

Burcu BİTERGE SÜT^1,*, Ayşe İKİNCİ KELE޲

Oncologie, Vol.22, No.3, pp. 147-154, 2020, DOI:10.32604/oncologie.2020.014449

Abstract Components of the protein synthesis machinery are subjected to alterations in cancer cells. eEF1D gene, which lies within the frequently amplified 8q24 locus, is one of the subunits of the human eukaryotic elongation factor complex. This study aimed to evaluate the prognostic and predictive significance of eEF1D in breast cancer using in silico analysis tools. For this purpose, we analyzed genomic alterations of the eEF1D gene using TCGA datasets via cBioPortal. Histopathological analysis was performed on patient tissue images obtained from cBioPortal and the Human Protein Atlas. Survival analysis was carried out using the KM… More >

Chuanwei Xu¹, Renju Ding², Chuanping Xu^3,*

Oncologie, Vol.22, No.1, pp. 43-51, 2020, DOI:10.32604/oncologie.2020.012445

Abstract To analyze the effects of different surgical procedures for the treatment of thyroid cancer on the expression levels of serum interleukin-17 (IL-17), IL-35, soluble interleukin-2 receptor (SIL-2R), and the prognostic factors. Seventy-eight patients with differentiated thyroid cancer were selected and grouped as control group (CG) (n = 39, underwent subtotal thyroidectomy) and observation group (OG) (n = 39, underwent total thyroidectomy). The serum IL-17, IL-35, and SIL- 2R expression levels; the incidence of complications; and the differentiated thyroid carcinoma (DTC) relapse rate were compared between the two groups. The serum IL-17 and SIL-2R levels were… More >

Hui Zhang, Zhan Wang, Lin Liu, Fuqiang Zhang, Yuxin Song, Yaowen Qian^*

Oncologie, Vol.22, No.1, pp. 23-33, 2020, DOI:10.32604/oncologie.2020.012493

Abstract The expression changes of miR-625-3p and miR-449a in osteosarcoma patients after surgery is the critical study in this paper. Analysis of their prognosis and risk factors can be helpful in understanding the prognostic value for clinical purposes. Fifty-eight patients with osteosarcoma diagnosed in our hospital were considered as the research group (RG), and 52 health subjects at the same time were collected as the control group (CG). Fluorescence quantitative PCR (RTPCR) was employed to test the expression levels of miR-625-3p and miR-449a in the serum of subjects in both groups before surgery and patients in… More >

Kellan F. Clark¹, Matthew Risendal¹, Sharon Hill², Samuel Deem³

Canadian Journal of Urology, Vol.26, No.2, pp. 9715-9719, 2019

Abstract Introduction: The TNM staging system is used globally as the standard for interpreting the extent of cancer. Currently, T3a renal cell carcinoma is classified as tumor extending into the perinephric fat or renal vein. Prognostic outcomes may vary among renal cell carcinomas with renal vein involvement (RVI) versus those with perinephric fat involvement (PFI).
Materials and methods: We reviewed the medical records of all patients who underwent radical or partial nephrectomy at our institution by a single group of urologists between 2000 and 2014. After identifying those patients with T3a renal cell carcinoma, we further analyzed their… More >

Jun Wu^1,*, Kui Hu¹, Yiwei Cheng², Ji Wang¹, Chao Deng^2,*, Yuanhan Wang³

Structural Durability & Health Monitoring, Vol.13, No.3, pp. 317-329, 2019, DOI:10.32604/sdhm.2019.05571

Abstract Residual useful life (RUL) prediction is a key issue for improving efficiency of aircraft engines and reducing their maintenance cost. Owing to various failure mechanism and operating environment, the application of classical models in RUL prediction of aircraft engines is fairly difficult. In this study, a novel RUL prognostics method based on using ensemble recurrent neural network to process massive sensor data is proposed. First of all, sensor data obtained from the aircraft engines are preprocessed to eliminate singular values, reduce random fluctuation and preserve degradation trend of the raw sensor data. Secondly, three kinds More >

Faruk Tas, Senem Karabulut, Kayhan Erturk, Derya Duranyildiz

European Cytokine Network, Vol.29, No.2, pp. 52-58, 2018, DOI:10.1684/ecn.2018.0408

Abstract Leptin may support the proliferation and hinder the apoptosis of tumor cells. Although leptin expression has been studied in several human tumors, its potential clinical significance remains uncertain in patients with gastric carcinoma. Furthermore, the majority of available findings have been determined from preclinical studies using stomach carcinoma tissue section and, to date, few studies have evaluated the clinical significance of leptin in the serum or plasma of gastric carcinoma patients. In the current study, the serum concentration of soluble leptin was assessed in gastric carcinoma patients, and its contributions to the clinical parameters and… More >

Nataša Todorović-Raković, Marko Radulovic, Tijana Vujasinović, Jelena Milovanović, Dragica Nikolic-Vukosavljević

European Cytokine Network, Vol.28, No.4, pp. 151-156, 2017, DOI:10.1684/ecn.2018.0402

Abstract There is increasing evidence for the importance of immunity in breast cancer. IFNγ is expected to have a prognostic value based on its major role in innate and specific cell-mediated immunity. In this retrospective study, based on the 14-year follow-up of 73 patients with breast cancer after surgery and radiotherapy but no subsequent systemic therapy, we investigated the prognostic time dependence of intra-tumoural IFNγ mRNA and protein levels. Over the entire 14 years of follow-up, neither IFNγ mRNA nor protein was significantly associated with metastasis outcome by AUC and Cox regression criteria. However, evaluation of… More >

Baohong Yang^*1, Aiying Qin^†1, Kongyuan Zhang^‡, Haipeng Ren^*, Shuzhen Liu^*, Xiaolei Liu^§, Xiangpo Pan^¶, Guohua Yu^*

Oncology Research, Vol.25, No.9, pp. 1601-1606, 2017, DOI:10.3727/096504017X14928634401178

Abstract Epithelial growth factor receptor (EGFR) mutations are present in 10%–26% of non-small cell lung cancer (NSCLC) tumors and are associated with the response to tyrosine kinase inhibitors (TKIs). This study aimed to detect and quantify the presence of circulating tumor cells (CTCs) in EGFR-mutant NSCLC patients and investigate their possible role in providing prognostic information. Enrolled patients received erlotinib (150 mg) or gefitinib (250 mg) orally once daily as the first-line treatment. Serial blood samples were taken at baseline (CTC-d0) and on day 28 (CTC-d28) following the initiation of erlotinib/gefitinib for detection of CTCs using… More >